The Inactivated Vaccines Market was valued at US$ 40.6 billion in 2023 and is projected to grow at a CAGR of 5.7% from 2024 ...

Pandemic influenza remains a significant global health threat, as signalled by the circulation and cross-species transmission of avian influenza A(H5N1) viruses from the clade 2.3.4.4b, including ...

An in-house reverse-genetics generated H5N9 inactivated vaccine (SEP-22- N9) was evaluated for its vaccine efficacy in ...

CLEVELAND, Ohio — Eggs are disappearing from store shelves due to shortages caused by the avian flu outbreak, but never fear ...

In the type segment of the influenza vaccine market, the inactivated influenza vaccine category generated a significant revenue share in the influenza vaccine market in 2024. Notable influenza ...

VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives. The Quadrivalent Inactivated ...

Zydus on Wednesday announced that it is ready to launch the season’s first India’s Flu protection as per WHO recommended composition of quadrivalent influenza virus vaccines for use in the 2025 ...

“Zydus’s Quadrivalent Inactivated Influenza vaccine VaxiFlu-4 will offer seasonal protection against four new virus strains,” it added. “A quadrivalent vaccine, by covering strains of both ...

The pharmaceutical company’s quadrivalent inactivated influenza vaccine, VaxiFlu-4, has been developed at the Vaccine Technology Centre (VTC) in Ahmedabad and is being marketed by Zydus ...

VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives. The Quadrivalent Inactivated Influenza vaccine has been developed at the Vaccine Technology Centre (VTC ...

Zydus Lifesciences introduces India's first quadrivalent influenza vaccine, VaxiFlu-4, for protection against four new virus strains as per WHO recommendations. The vaccine, developed at Zydus's ...